The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis
The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis
复制标题
DOI：
10.1016/j.ejca.2008.11.003
复制
发表时间：
2009-04-01
影响因子：
8.4
通讯作者：
Capocaccia, Riccardo
中科院分区：
文献类型：
--
作者：
De Angelis, Roberta;Francisci, Silvia;Capocaccia, Riccardo
本文描述了EUROCARE-4数据库中癌症生存数据的收集、标准化和检查。还描述了估计相对存活率的方法。新诊断的欧洲癌症病例的发病率和生命状态数据来自23个国家的93个癌症登记处，涵盖151，400，000人（占参与国家人口的35%）。国际肿瘤疾病分类第三次修订版被用于详细说明肿瘤的地形和形态。使用多个程序广泛检查记录的一致性和兼容性;将标记的记录发回更正。一种算法为多种癌症分配标准化的序列号。只有首次恶性肿瘤被用来估计相对生存登记，年，性别和年龄特异性生命表。该数据库包含1978-2002年诊断的13，814，573例病例; 92%为恶性。因重大错误而排除的记录比例可忽略不计。在1995-2002年诊断的5，753，934例恶性成人病例中，5.3%为第二次或以后的癌症，2.7%仅从死亡证明中得知，0.4%在尸检时发现。其余5，278，670例病例进入生存分析，其中90%的病例在显微镜下得到证实，1.3%在不到5年的随访后被删失为存活。这些指标表明，自欧洲援外合作组织第三次会议以来，数据质量有所改善，令人满意。(C)2008爱思唯尔有限公司保留所有权利。
This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated.The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3. (C) 2008 Elsevier Ltd. All rights reserved.